SAN FRANCISCO, CA, UNITED STATES, January 13, 2026 /EINPresswire.com/ -- Bringing together public institutions, ...

Kos Biotechnology Partners ("Kos"), a global life sciences investment firm, today announced the closing of a financing round in Epikast, a premier provider of technology-enabled commercial and ...

European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...

Biotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make ...

F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced last week that it would more than triple ...

The University of Pennsylvania, German biotech firm BioNTech, and Osage University Partners, a Bala Cynwyd venture capital ...

UK biotech showed resilience in a tough 2025 for healthcare funding, suggesting investor interest could grow in 2026.

Chicago-based sepsis diagnosing biotech Prenosis announced two $20 million milestones this morning, Series A financing and a large government contract.

In biotech, as of 2024 the sector recorded turnover of more than €47.5 billion, equivalent to 2.23% of national GDP, with R&D investments reaching approximately €2 billion. In pharma, production value ...